Alio

Broomfield, CO, United States All United States companies → — Founded 2012

Medical Device / Hardware Specialty-Focused AI Wearables / RPM

Cardiology Endocrinology Nephrology

Endocrinology & Metabolic AI Patient Engagement & Education Wearables & Remote Monitoring (RPM)

Series C — Over $50 million

Claim this company

Products

Alio

Alio Inc.

Endocrinology & Metabolic AI

Alio Inc. offers an FDA-cleared, AI-powered remote patient monitoring platform featuring a wearable SmartPatch, Hub, and Portal for non-invasive, continuous data collection and analysis in patients with chronic conditions, especially those undergoing hemodialysis.

Contact vendor for pricing details.

See all 1 product →

About Alio

Alio is a medical technology company dedicated to delivering peace of mind to individuals with chronic conditions through its non-invasive, wireless remote patient monitoring platform. The company leverages its proprietary SmartPatch™ technology, which is powered by artificial intelligence (AI), to collect and analyze clinical-grade, real-time physiological data. This innovative approach aims to empower physicians with actionable insights and predictive analytics, facilitating targeted interventions that can lead to improved health outcomes and a reduction in avoidable hospitalizations.

The Alio platform is FDA-cleared and capable of monitoring multiple critical health metrics without the need for traditional invasive methods like blood draws. These metrics include hematocrit, hemoglobin, potassium, auscultation, heart rate, and skin temperature. The system comprises a wearable SmartPatch, a home-based hub for data collection, and a clinician-facing portal that allows healthcare teams to remotely track patient data and receive alerts for abnormalities.

Initially focused on the management of end-stage kidney disease (ESKD) and dialysis patients, Alio is actively expanding its indications to serve a broader range of individuals with chronic conditions such as chronic kidney disease, heart failure, and peripheral vascular disease. By providing continuous, comprehensive monitoring, Alio seeks to transform chronic disease management by offering greater visibility into a patient’s health outside of clinical settings, ultimately enhancing care coordination and patient quality of life.

Focus Areas

Remote Patient Monitoring Wearable Medical Devices Chronic Disease Management End-Stage Kidney Disease (ESKD) Dialysis Complications AI-driven Health Insights Non-invasive Monitoring Hematocrit Monitoring Hemoglobin Monitoring Potassium Monitoring Auscultation Heart Rate Monitoring Skin Temperature Monitoring

Business Intelligence

Key Investors	Widjaja Family, Chase Field, LLC, Thomas Krebs, QB3, AIoT Health, Asland Capital Partners, Zekavat Investment Group, Maryland.gov, TEDCO, UCSF Rosenman Institute, iO life ventures
Partnerships	NHS (UK), US Renal Care, various health systems and dialysis centers globally
Technology	The Alio platform consists of a wearable SmartPatch, a bedside Hub, and a cloud-based clinician Portal. The SmartPatch uses multiple sensor technologies (microphone, accelerometer, thermistor, LEDs, photodetectors) for non-invasive data collection. Data is transmitted wirelessly via Bluetooth to the Hub, then uploaded to the Alio Cloud via cellular connection. Cloud-based AI algorithms analyze the data to provide actionable insights and notifications to clinicians through the Portal.
FDA Clearances	2 cleared products (estimated)

What Physicians Need to Know

Remote Patient Monitoring (RPM)

Alio offers an end-to-end remote monitoring platform, powered by its SmartPatch technology, a bedside Hub, and a clinician web Portal. This system enables proactive, non-invasive, and continuous monitoring of patients, particularly those with chronic conditions like End-Stage Kidney Disease (ESKD). It provides actionable notifications to care teams.

Wearable Medical Devices

The core of Alio's RPM solution is the SmartPatch, a flexible, silicone-encased wearable device designed for 24/7 wear. It is placed over the dialysis access site (or calf in expanded trials) and wirelessly transmits clinical-grade data. The system is 'plug and play,' requiring no patient interaction for data transmission.

Chronic Disease Management

Initially focused on improving outcomes for patients with ESKD, Alio's platform is expanding its capabilities to serve a wider range of patients with chronic conditions, including chronic kidney disease (CKD) and heart failure. The goal is to provide critical health insights to help clinicians intervene earlier and reduce hospitalizations.

End-Stage Kidney Disease (ESKD) & Dialysis Complications

Alio specifically addresses the challenges of ESKD and dialysis complications by non-invasively monitoring critical metrics. This includes identifying early warning signs of issues like fluid overload, dyskalemia (potassium imbalance), and vascular access health, which are common causes of hospitalizations in this patient population.

AI-driven Health Insights

Alio's platform leverages cloud-based artificial intelligence (AI) algorithms to analyze the data collected by the SmartPatch. This analysis generates actionable insights, predictive analytics, and timely notifications for dialysis clinics and care teams, enabling targeted interventions.

Non-invasive Monitoring

A key differentiator, Alio's technology provides clinical-grade monitoring without the need for blood draws, finger pricks, or microneedles. This significantly improves the patient experience and compliance.

Comprehensive Parameter Monitoring

The SmartPatch is FDA-cleared to non-invasively monitor multiple vital parameters, including hematocrit, hemoglobin, potassium (world's first non-invasive potassium monitor), auscultation sound data (from vascular access), heart rate, and skin temperature. Future expansions are planned for additional metrics like SpO2, blood volume, and blood pressure.

Physician Tip

For physicians, Alio's platform offers a significant advancement in managing chronic conditions, particularly ESKD. The continuous, non-invasive, multi-metric data collection, coupled with AI-driven actionable insights and alerts, enables earlier detection of complications like fluid imbalances or vascular access issues. This can lead to more timely interventions, potentially reducing preventable hospitalizations and improving patient outcomes. The patient-friendly SmartPatch design enhances compliance, providing a more complete picture of patient health outside of clinic visits. The clinician portal streamlines data review and allows for customized alert ranges, integrating seamlessly into existing workflows and supporting both in-center and home dialysis management.

Alio's platform is designed for integration into existing healthcare infrastructures and workflows. The system comprises a SmartPatch, a bedside Hub, and a web Portal for clinicians. Partnerships, such as with Carium, indicate a focus on connecting with Care Experience Platforms to enhance chronic care management and accessibility. The web portal provides notifications to dialysis staff, suggesting a clear pathway for integrating these insights into clinical decision-making.

At a glance

Founded 2012

HQ Broomfield, CO, United States · United States

Team size approximately 50

CEO David Kuraguntla

Funding Series C — Over $50 million

FDA clearances 2 (estimated)

Products 1

Products by Alio

1 product in the directory

Alio

Alio Inc.

Endocrinology & Metabolic AI

Contact vendor for pricing details.

What the Web Says

Alio (formerly known as 'Vivante Health' or 'Vivante') receives mixed reviews. While their digital gut health program is generally praised for its effectiveness and user-friendliness, the company culture and management practices have drawn significant criticism from current and former employees. There's a clear distinction between positive product feedback and negative employer feedback.

Overall: Mixed

Strengths

Effective and comprehensive gut health program (Vivante Health/Alio Care)
User-friendly app interface and personalized support
Helpful and knowledgeable health coaches/dietitians
Positive impact on users' digestive health and quality of life
Good benefits package for employees (e.g., unlimited PTO, health benefits)
Mission-driven company with a focus on improving health outcomes

Limitations

High turnover rate and frequent layoffs reported by employees
Issues with management, leadership, and communication within the company
Lack of clear direction and strategy, leading to employee frustration
Inconsistent work-life balance and high workload for some roles
Concerns about company culture, described as 'toxic' by some
Rapid changes in company structure and priorities

Based on reviews from: G2, Glassdoor, Capterra, Reddit, Healthcare IT News (mentions of Vivante Health)

Last updated: 2026-07-17

Videos

News, demos, and interviews about Alio.

Loading videos...

Videos load interactively. If none appear, search YouTube for Alio →

View all on YouTube

Press & Coverage

Clinical Trials Arena

Alio starts trial to expand label for remote monitoring device

Alio has launched the CAVA study to expand the use of its SmartPatch technology for non-invasive monitoring of health metrics from the calf in dialysis patients without vascular access sites. The SmartPatch was previously cleared by the FDA for arm-based monitoring and can measure various health metrics including hemoglobin, hematocrit, and potassium.

2024-09

Business Wire

Alio Launches Calibration and Validation (CAVA) Study to Expand Alio Platform's FDA Clearance Beyond the Vascular Access for Use in a Broader Range of Patients

Alio, Inc. announced the launch of its multi-center and international CAVA study to expand its FDA clearance beyond dialysis patients with vascular access to a broader range of patients with chronic conditions. The study will assess the SmartPatch for non-invasive monitoring of critical health metrics from the calf, building on previous FDA clearances for arm-based monitoring.

2024-09

Medical Product Outsourcing

Alio's SmartPatch Technology Under Review in New Study

Alio Inc. has initiated the CAVA study to expand its FDA SmartPatch clearance beyond vascular access use, aiming to serve a wider range of patients with chronic conditions like chronic kidney disease and heart failure. The SmartPatch is FDA-cleared to monitor various metrics non-invasively, including hematocrit, hemoglobin, and potassium.

2024-10

PMC

Remote management of anaemia in patients with end-stage kidney disease using a wearable, non-invasive sensor

This study evaluates the accuracy of the Alio SmartPatchu2122, a non-invasive remote monitoring device, in measuring hemoglobin and hematocrit levels in hemodialysis patients. The FDA-cleared SmartPatch also tracks heart rate, auscultation, skin temperature, and is the world's first non-invasive monitor for abnormal potassium.

2024-11

Renal Interventions

Significant milestones of the Alio SmartPatchu2122 to enable remote monitoring of patients with chronic kidney disease

The Alio SmartPatchu2122 is an FDA-cleared, non-invasive, wireless medical device that remotely monitors dialysis access, providing timely notifications for healthcare providers. It tracks physiological metrics including basic vitals, hematologic parameters, and potassium, and uses machine learning to analyze acoustic samples for patency detection.

2024-04

PR Newswire

Alio Announces Expansion of Operations in GCC Market to the UAE Through Partnership with GulfDrug

Alio, Inc. announced a strategic partnership with GulfDrug, a leading medical supplier in the United Arab Emirates (UAE), to expand its operations in the GCC market.

2024-01

BioSpace

Alio's Remote Monitoring Platform Now Notifies Clinicians of Atypical Acoustic Data from Patients with Vascular Access

Alio, Inc. released a new feature for its remote monitoring platform that notifies clinical care teams about atypical acoustic data from a patient's vascular access site. This feature builds on the platform's FDA clearance to collect auscultation data and aims to enable targeted interventions and reduce hospitalizations.

2023-09

PR Newswire

Alio Secures Commercial Customer, Premier Dialysis, Further Extending its Reach Within the Kidney Disease Landscape

Alio, Inc. announced its official launch with commercial customer Premier Dialysis, aiming to improve the quality of life for dialysis patients through better management of their condition. Premier Dialysis will utilize Alio's Portal and SmartPatch for its hemodialysis patient population.

2023-09

Frequently Asked Questions

What specific medical conditions and metrics does Alio's remote patient monitoring platform address?

Alio's SmartPatch platform is primarily designed for patients with End-Stage Kidney Disease (ESKD) undergoing dialysis, offering continuous, non-invasive remote monitoring. It tracks critical metrics such as hematocrit, hemoglobin, potassium levels, auscultation, heart rate, and skin temperature to help manage dialysis complications and other chronic conditions.

How does Alio ensure regulatory compliance and data security for its wearable medical devices and AI-driven insights?

Alio's SmartPatch is FDA-cleared, with clearances for various metrics including skin temperature, auscultation, heart rate, hematocrit, hemoglobin, and potassium monitoring. The system transmits encrypted and HIPAA-compliant data from the SmartPatch and hub to a secure cloud-based clinician portal, ensuring patient data privacy and security.

What kind of AI-driven health insights does the Alio platform provide to clinicians for chronic disease management?

Alio's platform leverages artificial intelligence to analyze the clinical-grade data collected from the SmartPatch, generating actionable insights, predictive analytics, and notifications. These insights enable care teams to proactively intervene, optimize patient outcomes, and potentially reduce hospitalizations for patients with chronic conditions like ESKD.

What is Alio's pricing model for healthcare providers, and what support can we expect for implementation and ongoing use?

Specific pricing models for healthcare providers are not publicly disclosed and typically require direct inquiry with Alio. However, the platform includes a clinician portal for managing and monitoring patients. Alio aims to provide a patient-friendly solution that integrates into existing workflows, suggesting support for seamless deployment and ongoing use.

What partnerships has Alio established within the healthcare industry, and how do they enhance its offerings?

Alio has formed strategic partnerships with companies like Carium, a care experience platform, to expand access to its remote patient monitoring for chronic conditions. They also collaborate with organizations such as Lifeline Vascular Care for dialysis access monitoring and clinical trials, and GulfDrug for international market expansion, enhancing their reach and service delivery.

What is the company's stability and long-term vision, particularly regarding expansion beyond ESKD and new monitoring capabilities?

Alio, founded in 2012, is a Series C company that has raised over $50 million in funding, indicating solid financial stability. The company is actively conducting studies to expand its FDA clearance beyond vascular access sites and to include monitoring for a broader range of chronic conditions like heart failure, demonstrating a vision for wider application and continuous innovation.

Related Companies

Suggest an Edit →